The anti-malaria drug was as soon as touted by former US President Donald Trump as an efficient remedy for COVID-19. Now Oklahoma is attempting to return $2m price of it.
The Oklahoma legal professional common’s workplace is making an attempt to return $2m price of a malaria drug as soon as touted by former United States President Donald Trump as an efficient remedy for COVID-19, a spokesman stated Wednesday.
Alex Gerszewski, a spokesman for Legal professional Normal Mike Hunter, stated Hunter is making an attempt to barter a return of the 1.2 million hydroxychloroquine drugs Oklahoma acquired in April from a California-based provider, FFF Enterprises. He stated the workplace was performing on a request from the Oklahoma State Division of Well being, which authorised the acquisition.
A spokeswoman for FFF Enterprises didn’t instantly return a message Wednesday in search of remark.
The try by Oklahoma to return the hydroxychloroquine was first reported by the web information publication The Frontier.
Republican Governor Kevin Stitt defended the acquisition final yr, saying the drug was exhibiting some promise as a remedy in early March and he didn’t wish to miss a possibility to accumulate it.
“I used to be being proactive to try to shield Oklahomans,” Stitt stated on the time.
The drug has since been proven to have little or no impact on extreme instances of COVID-19, and a former state well being official chalked up Oklahoma’s buy to one thing that occurs in “the fog of conflict”.
Whereas governments in at the very least 20 different states obtained greater than 30 million doses of the drug by way of donations from the federal reserve or non-public corporations, Oklahoma and Utah purchased them from non-public pharmaceutical corporations.
Then-Utah Governor Gary Herbert, a Republican, initially defended the state’s $800,000 buy of 20,000 packets of hydroxychloroquine compounded with zinc, however later cancelled an extra plan to spend $8m extra to purchase 200,000 extra remedies. The state then managed to safe a refund on the $800,000 no-bid contract it signed with an area pharmacy firm that had been selling the medicine.
The CEO of the pharmacy firm has since pleaded responsible to a federal misdemeanor for mislabelling the drug imported from China. Dan Richards, the operator of Meds In Movement, acknowledged receiving massive quantities of the drug that had been from an unregistered producer in China and that had been incorrectly labelled as an natural complement.
His lawyer has stated he was attempting to assist procure as a lot of the product as attainable as a result of on the time it appeared like a promising remedy for the coronavirus.